Compare Nuvalent Inc (NUVL) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Boston Beer Company Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Boston Beer Company Inc trades at $170.75 (market cap $1.88B). The key difference: Nuvalent Inc is far larger — about 5.2× Boston Beer Company Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| NUVL | SAM | |
|---|---|---|
Market Cap | $9.81B | $1.88B |
Sector | Technology | Consumer Staples |
52-Week High | $123.96 | $260.05 |
52-Week Low | $72.16 | $161.08 |
Enterprise Value | $8.52B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
